These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. de Bodinat C; Guardiola-Lemaitre B; Mocaër E; Renard P; Muñoz C; Millan MJ Nat Rev Drug Discov; 2010 Aug; 9(8):628-42. PubMed ID: 20577266 [TBL] [Abstract][Full Text] [Related]
8. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. Kasper S; Hamon M World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935 [TBL] [Abstract][Full Text] [Related]
10. [Agomelatine]. Tessmer M Med Monatsschr Pharm; 2009 Aug; 32(8):282-8. PubMed ID: 19777735 [TBL] [Abstract][Full Text] [Related]
11. Agomelatine: a preliminary review of a new antidepressant. Zupancic M; Guilleminault C CNS Drugs; 2006; 20(12):981-92. PubMed ID: 17140278 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Rouillon F Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S31-5. PubMed ID: 16436938 [TBL] [Abstract][Full Text] [Related]
13. Agomelatine, a melatonin agonist with antidepressant properties. Dubovsky SL; Warren C Expert Opin Investig Drugs; 2009 Oct; 18(10):1533-40. PubMed ID: 19758108 [TBL] [Abstract][Full Text] [Related]
14. [Further evidence of the efficacy of the antidepressant Valdoxan (agomelatine) compared with conventional antidepressive drugs (from the ECNP held in Istanbul, 15 September 2009)]. Rohmer JG Encephale; 2009 Dec; 35(6):611. PubMed ID: 20004293 [No Abstract] [Full Text] [Related]
15. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Olié JP; Kasper S Int J Neuropsychopharmacol; 2007 Oct; 10(5):661-73. PubMed ID: 17477888 [TBL] [Abstract][Full Text] [Related]
16. Agomelatine: efficacy at each phase of antidepressant treatment. Kennedy SH CNS Drugs; 2009; 23 Suppl 2():41-7. PubMed ID: 19708725 [TBL] [Abstract][Full Text] [Related]
17. Agomelatine targets a range of major depressive disorder symptoms. Dubocovich ML Curr Opin Investig Drugs; 2006 Jul; 7(7):670-80. PubMed ID: 16869122 [TBL] [Abstract][Full Text] [Related]
18. Treating each and every depressed patient. Kennedy SH J Psychopharmacol; 2008 Sep; 22(7 Suppl):19-23. PubMed ID: 18753279 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. Stein DJ; Picarel-Blanchot F; Kennedy SH Hum Psychopharmacol; 2013 Mar; 28(2):151-9. PubMed ID: 23532747 [TBL] [Abstract][Full Text] [Related]
20. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. Kennedy SH; Rizvi SJ CNS Drugs; 2010 Jun; 24(6):479-99. PubMed ID: 20192279 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]